Clinical Outcomes of Lung Cancer Patients After Lobectomy Surgery Using Thoracotomy and VATS Methods at Persahabatan Hospital from 2021 to 2024
DOI:
https://doi.org/10.51601/ijhp.v6i2.643Abstract
Lobectomy is the primary surgical treatment for lung cancer and can be performed using thoracotomy or video-assisted thoracoscopic surgery (VATS). This study aimed to describe patient characteristics, preoperative clinical conditions, intraoperative findings, and postoperative outcomes of lung cancer patients undergoing lobectomy using both techniques at Persahabatan General Hospital from 2021 to 2024. A retrospective descriptive cohort study was conducted involving 49 patients, consisting of thoracotomy (n=35) and VATS (n=14). Data included demographic characteristics, comorbidities, lung function, cancer type, intraoperative variables, and postoperative outcomes, which were analyzed descriptively. The mean age was 50 ± 12.2 years with a median of 54 years, and most patients were in late adulthood. Males predominated in the thoracotomy group, while females were more common in the VATS group. Smoking history was frequent, whereas diabetes mellitus and COPD were only found in the thoracotomy group. Most patients had normal preoperative lung function and primary lung cancer, although lung metastases were more common in thoracotomy cases. Thoracotomy was more frequently associated with longer operative time (>3 hours), greater intraoperative blood loss, and higher need for blood transfusion compared to VATS, which more often had shorter operative duration (≤3 hours). Postoperative morbidity was low in both groups, and mortality was similar at 2%. Length of hospital stay was generally shorter in the VATS group compared to thoracotomy. In conclusion, thoracotomy is more often used in complex cases, while VATS offers advantages in selected patients, particularly in terms of operative efficiency and recovery, supporting individualized surgical decision-making.
Downloads
References
[1] B. C. Bade and C. S. Dela Cruz, “Lung Cancer 2020,” Clin. Chest Med., vol. 41, no. 1, pp. 1–24, Mar. 2020, doi: 10.1016/j.ccm.2019.10.001.
[2] N. Zhou, Y. Xu, Y. Huang, G. Ye, L. Luo, and Z. Song, “Comprehensive genomic profiling of Chinese lung cancer characterizes germline-somatic mutation interactions influencing cancer risk,” J. Transl. Med., vol. 23, no. 1, p. 199, Feb. 2025, doi: 10.1186/s12967-025-06096-z.
[3] P. J. Mazzone et al., “Screening for Lung Cancer: CHEST Guideline and Expert Panel Report,” Chest, vol. 153, no. 4, pp. 954–985, Apr. 2018, doi: 10.1016/j.chest.2018.01.016.
[4] J. Joseph and L. W. A. Rotty, “Kanker Paru: Laporan Kasus,” Medical Scope Journal, vol. 2, no. 1, Jul. 2020, doi: 10.35790/msj.2.1.2020.31108.
[5] H. Ito et al., “Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer,” J. Thorac. Cardiovasc. Surg., vol. 161, no. 1, pp. 281–290, Jan. 2021, doi: 10.1016/j.jtcvs.2019.12.072.
[6] M. S. Kent et al., “Pulmonary Open, Robotic, and Thoracoscopic Lobectomy (PORTaL) Study,” Ann. Surg., vol. 277, no. 3, pp. 528–533, Mar. 2023, doi: 10.1097/SLA.0000000000005115.
[7] C. E. Bravo Iñiguez et al., “Thirty-Day Mortality After Lobectomy in Elderly Patients Eligible for Lung Cancer Screening,” Annals of Thoracic Surgery, vol. 101, no. 2, pp. 541–546, Feb. 2016, doi: 10.1016/j.athoracsur.2015.08.067.
[8] W. Shao, Z. Zhang, J. Zhang, H. Feng, C. Liang, and D. Liu, “Charlson comorbidity index as a predictor of short-term outcomes after pulmonary resection,” J. Thorac. Dis., vol. 12, no. 11, pp. 6670–6679, Nov. 2020, doi: 10.21037/jtd-20-2264.
[9] Novianty Kusumawardani, Widhy Yudistira, and Ike Rahmawaty Alie, “Karakteristik dan Faktor Risiko Pasien Kanker Paru di RSUD Al-Ihsan Provinsi Jawa Barat Tahun 2022,” Bandung Conference Series: Medical Science, vol. 4, no. 1, pp. 55–61, Feb. 2024, doi: 10.29313/bcsms.v4i1.10372.
[10] M. Farhan Irhamsyah H., “Karakteristik Penderita Kanker Paru Primer Periode Januari 2017 – Desember 2019,” Universitas Hasanuddin, Makassar, 2020.
[11] C. Piwkowski et al., “Ninety-Day Mortality of Thoracoscopic vs Open Lobectomy: A Large Multicenter Cohort Study,” in Annals of Thoracic Surgery, Elsevier Inc., Mar. 2023, pp. 693–699. doi: 10.1016/j.athoracsur.2022.07.050.
[12] N. A. Ismail, N. H. Zailani, and S. Y. Soon, “Less is more: Video Assisted Thoracoscopic (VATS) Lobectomy vs Thoracotomy- a Clinical and Cost Analysis in a Developing Country,” Scholars Journal of Applied Medical Sciences, vol. 08, no. 05, pp. 1361–1364, May 2020, doi: 10.36347/sjams.2020.v08i05.037.
[13] C. Cao, R. H. Petersen, and T. D. Yan, “Learning curve for video-assisted thoracoscopic lobectomy,” J. Thorac. Cardiovasc. Surg., vol. 147, no. 5, p. 1727, May 2014, doi: 10.1016/j.jtcvs.2014.01.038.
[14] A. L. Potter et al., “The Increasing Adoption of Minimally Invasive Lobectomy in the United States,” in Annals of Thoracic Surgery, Elsevier Inc., Aug. 2023, pp. 222–229. doi: 10.1016/j.athoracsur.2022.09.032.
[15] F. Bray et al., “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 74, no. 3, pp. 229–263, May 2024, doi: 10.3322/caac.21834.
[16] P. Agostini et al., “Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors?,” Thorax, vol. 65, no. 9, pp. 815–818, Sep. 2010, doi: 10.1136/thx.2009.123083.
[17] A. Scherpereel et al., “Ers/Ests/Eacts/Estro guidelines for the management of malignant pleural mesothelioma,” Jun. 01, 2020, European Respiratory Society. doi: 10.1183/13993003.00953-2019.
[18] R. P. Young and R. J. Hopkins, “Chronic obstructive pulmonary disease (COPD) and lung cancer screening,” Jun. 01, 2018, AME Publishing Company. doi: 10.21037/tlcr.2018.05.04.
[19] S. Liu, S. Li, Y. Tang, R. Chen, and G. Qiao, “Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis,” 2023, Frontiers Media SA. doi: 10.3389/fmed.2023.1152421.
[20] L. Cagini, S. Ceccarelli, V. Tassi, J. Vannucci, and F. Puma, “Thoracotomy versus VATS: short term outcomes from a large randomized controlled trial,” Video. Assist. Thorac. Surg., vol. 3, pp. 24–24, Jun. 2018, doi: 10.21037/vats.2018.05.02.
[21] J. Xu et al., “Perioperative comparison of video-assisted thoracic surgery and open lobectomy for pT1-stage non-small cell lung cancer patients in China: A multi-center propensity score-matched analysis,” Transl. Lung Cancer Res., vol. 10, no. 1, pp. 402–414, Jan. 2021, doi: 10.21037/tlcr-20-1132.
[22] M. Salati and A. Brunelli, “Risk Stratification in Lung Resection,” Curr. Surg. Rep., vol. 4, no. 11, p. 37, Nov. 2016, doi: 10.1007/s40137-016-0158-x.
[23] S. Li, K. Zhou, Y. Lai, C. Shen, Y. Wu, and G. Che, “Estimated intraoperative blood loss correlates with postoperative cardiopulmonary complications and length of stay in patients undergoing video-assisted thoracoscopic lung cancer lobectomy: a retrospective cohort study,” BMC Surg., vol. 18, no. 1, p. 29, Dec. 2018, doi: 10.1186/s12893-018-0360-0.
[24] M. Salama and M. R. Mueller, “Enhanced recovery in lung surgery: coaxial versus conventional chest drains following video-assisted thoracoscopic surgery lobectomy—a prospective randomized trial,” J. Thorac. Dis., vol. 17, no. 11, pp. 10262–10271, Nov. 2025, doi: 10.21037/jtd-2025-1169.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aqilah Nurahmah Argani, Yanto Sandy Tjang, Feda Anisah Makkiyah, Muttia Amalia, Erlang Samoedro
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
